UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): ~~May~~July 102, 2007

ABRAXIS BIOSCIENCE, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

0-33407

68-0389419

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

11755 Wilshire Boulevard, Suite 2000

Los Angeles, California 90025

(Address of Principal Executive Offices) (Zip Code)

(310) 883-1300

(Registrant’s Telephone Number, Including Area Code)

Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02

Results of Operations and Financial Condition.

On ~~May~~July 102, 2007, Abraxis BioScience, Inc. (the “Company”) issued a press release announcing its ~~financial~~plan ~~results~~to ~~for~~separate ~~the~~into ~~quarter~~two ~~ended~~independent ~~March 31,~~public ~~2007~~companies. A copy of the press release is furnished (but not filed) as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

In ~~addition~~the topress ~~reporting financial results in accordance with generally accepted accounting principles (“GAAP”)~~release, the Company presented ~~certain~~adjusted EBITDA, a non-GAAP financial ~~measures~~measure, ~~including~~which ~~adjusted~~is defined as net income, ~~per~~excluding ~~diluted~~the ~~share~~impact ~~which~~of isdepreciation ~~comprised~~and ofamortization, ~~reported~~interest ~~diluted~~expense ~~earnings~~net ~~per~~of ~~share~~interest ~~excluding~~income ~~the~~and ~~impact~~other ofincome, ~~non-cash~~income ~~amortization~~tax ~~of merger~~expense, stock-~~related~~based ~~intangible~~compensation ~~assets~~expense, ~~direct~~ merger ~~and transaction-related~~ costs, ~~non~~merger related in-~~cash~~process ~~stock~~research ~~compensation~~and ~~expense~~development charge, minority interests, equity interests in Drug Source Company, LLC and ~~non~~pre-~~cash~~launch ~~amortization~~costs ofassociated ~~acquired~~with ~~intangible~~the ~~assets~~Puerto Rico manufacturing facility. The Company ~~believes~~uses ~~that~~adjusted ~~its~~EBITDA ~~presentation~~to ofprovide ~~non-GAAP financial~~meaningful ~~measures~~supplemental ~~provides useful supplementary~~ information to investors in understanding the underlying operating performance of the ~~Company~~business and ~~facilitates~~facilitate additional analysis by investors. The Company ~~also~~believes ~~uses~~that ~~these~~adjusted ~~non-GAAP~~EBITDA ~~financial~~can ~~measures internally~~assist ~~for~~management and investors in assessing the financial operating, ~~budgeting~~performance and underlying ~~financial~~strength ~~planning~~of ~~purposes~~the Company’s core business. ~~The~~Adjusted ~~non-GAAP~~EBITDA ~~financial~~is ~~measures~~not ~~are~~a inrecognized ~~addition~~term ~~to,~~under GAAP and should not abe ~~substitute~~considered ~~for~~in isolation of, or ~~superior~~as toa substitute for, ~~measures~~the ofinformation ~~financial~~prepared ~~performance~~and ~~calculated~~presented in accordance with GAAP. A ~~reconciliation~~ reconciliation of GAAP net income to adjusted ~~net~~EBITDA ~~income~~ is included in the press release.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits

Exhibit		Description
99.1		Press release issued by Abraxis BioScience, Inc., dated ~~May~~July 102, 2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Index to Exhibits

Exhibit		Description
99.1		Press release issued by Abraxis BioScience, Inc., dated ~~May~~July 102, 2007

ABRAXIS BIOSCIENCE, INC.

Date: May 10, 2007

/s/ Lisa Gopalakrishnan

Date: July 2, 2007

/s/ Lisa Gopalakrishnan

Lisa Gopalakrishnan

Chief Financial Officer

Filing Compare · APP Pharmaceuticals, Inc.